Palatin Technologies (PTN)
(Delayed Data from AMEX)
$2.29 USD
-0.06 (-2.55%)
Updated May 10, 2024 04:00 PM ET
After-Market: $2.26 -0.03 (-1.31%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
PTN 2.29 -0.06(-2.55%)
Will PTN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PTN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PTN
Palatin (PTN) Up 15% on Results From Dry Eye Disease Study
Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?
PTN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates
Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates
Other News for PTN
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Palatin Technologies (PTN)
Buy Rating Endorsed for Palatin Technologies Amidst Promising Obesity Treatment Advancements
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
Palatin's IND application for obesity candidate granted FDA clearance